首页 > 最新文献

European Cardiology Review最新文献

英文 中文
Clinical Management of Non-alcoholic Steatohepatitis and the Role of the Cardiologist 非酒精性脂肪性肝炎的临床治疗与心脏病专家的作用
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-12-22 DOI: 10.15420/ecr.2023.22
Carlos Millán-Rodríguez, Carlos Palacios Castelló Palacios Castelló, M. Caballero-Valderrama, Gonzalo Barón Esquivias
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of fat-associated liver conditions that increase risk of cardiovascular disease and mortality. The diagnosis and clinical management of NAFLD remain a challenge for cardiologists. Our group performed a systematic review in PubMed of the relationship between NAFLD and cardiovascular disease, identifying 35 relevant articles. NAFLD is likely to be the liver’s expression of metabolic syndrome and increases the risk of several cardiovascular diseases, including coronary artery disease, stroke, heart failure and electrical disorders, and chronic kidney disease. Echocardiography is a useful tool to check early subclinical abnormalities in heart structure and function linked to NAFLD progression, such as cardiac diastolic impairment or epicardial fat thickness. Currently, NAFLD is predominantly managed by lifestyle changes with the aim of weight loss, based on the Mediterranean diet and intense exercise training. Despite the lack of approved drugs for NAFLD, new potential treatments, mainly glucagon-like peptide-1 agonists or sodium–glucose cotransporter 2 inhibitors, could change cardiologists’ approach to this pathology.
非酒精性脂肪肝(NAFLD)是一系列与脂肪相关的肝脏疾病,会增加心血管疾病的风险和死亡率。非酒精性脂肪肝的诊断和临床管理仍然是心脏病专家面临的一项挑战。我们的研究小组在 PubMed 上对非酒精性脂肪肝与心血管疾病之间的关系进行了系统综述,发现了 35 篇相关文章。非酒精性脂肪肝可能是代谢综合征在肝脏中的表现,会增加多种心血管疾病的风险,包括冠心病、中风、心力衰竭、心电紊乱和慢性肾病。超声心动图是检查与非酒精性脂肪肝进展有关的心脏结构和功能早期亚临床异常(如心脏舒张功能受损或心外膜脂肪厚度)的有效工具。目前,非酒精性脂肪肝主要通过改变生活方式来控制,目的是通过地中海饮食和高强度运动训练来减轻体重。尽管非酒精性脂肪肝的治疗药物尚未获得批准,但新的潜在治疗方法(主要是胰高血糖素样肽-1激动剂或钠-葡萄糖共转运体2抑制剂)可能会改变心脏病专家对这一病症的治疗方法。
{"title":"Clinical Management of Non-alcoholic Steatohepatitis and the Role of the Cardiologist","authors":"Carlos Millán-Rodríguez, Carlos Palacios Castelló Palacios Castelló, M. Caballero-Valderrama, Gonzalo Barón Esquivias","doi":"10.15420/ecr.2023.22","DOIUrl":"https://doi.org/10.15420/ecr.2023.22","url":null,"abstract":"Non-alcoholic fatty liver disease (NAFLD) is a spectrum of fat-associated liver conditions that increase risk of cardiovascular disease and mortality. The diagnosis and clinical management of NAFLD remain a challenge for cardiologists. Our group performed a systematic review in PubMed of the relationship between NAFLD and cardiovascular disease, identifying 35 relevant articles. NAFLD is likely to be the liver’s expression of metabolic syndrome and increases the risk of several cardiovascular diseases, including coronary artery disease, stroke, heart failure and electrical disorders, and chronic kidney disease. Echocardiography is a useful tool to check early subclinical abnormalities in heart structure and function linked to NAFLD progression, such as cardiac diastolic impairment or epicardial fat thickness. Currently, NAFLD is predominantly managed by lifestyle changes with the aim of weight loss, based on the Mediterranean diet and intense exercise training. Despite the lack of approved drugs for NAFLD, new potential treatments, mainly glucagon-like peptide-1 agonists or sodium–glucose cotransporter 2 inhibitors, could change cardiologists’ approach to this pathology.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"9 4","pages":""},"PeriodicalIF":3.0,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138944741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidence-based Management of Left Main Coronary Artery Disease 左冠状动脉主干疾病的循证管理
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-12-19 DOI: 10.15420/ecr.2023.36
G. Torres-Ruiz, Nuria Mallofré-Vila, P. Rojas-Flores, Pablo Carrión-Montaner, E. Bosch-Peligero, Daniel Valcárcel-Paz, Ada Cardiel-Perez, J. Guindo-Soldevila, Antonio Martínez-Rubio
Left main coronary artery disease (LMCAD) is associated with high morbidity and mortality due to the large myocardial mass at risk. Although medical treatment may be an option in selected low-risk patients, revascularisation is recommended to improve survival in the majority of patients presenting with a significant left main stenosis. In the past decade, multiple randomised clinical trials and meta-analyses have compared coronary artery bypass grafting surgery (CABG) versus percutaneous coronary intervention (PCI), finding controversial results. The strategy for LMCAD revascularisation is still challenging. Coronary anatomy complexity, clinical features and patient preferences are key elements to be considered by the heart team. The current guidelines define CABG as standard therapy, but the continuous improvements in PCI techniques, the use of intracoronary imaging and functional assessment make PCI a feasible alternative in selected patients, particularly in those with comorbidities and contraindications to CABG. This review analyses the most important studies comparing CABG versus PCI in patients with LMCAD.
左主干冠状动脉疾病(LMCAD)由于存在巨大的心肌风险,因此发病率和死亡率都很高。虽然药物治疗可能是部分低风险患者的选择,但对于大多数左主干严重狭窄的患者,建议进行血管重建以提高生存率。过去十年间,多项随机临床试验和荟萃分析对冠状动脉旁路移植手术(CABG)和经皮冠状动脉介入治疗(PCI)进行了比较,结果存在争议。LMCAD 血管再通的策略仍然具有挑战性。冠状动脉解剖的复杂性、临床特征和患者的偏好是心脏团队需要考虑的关键因素。目前的指南将 CABG 定义为标准疗法,但 PCI 技术的不断改进、冠状动脉内成像和功能评估的使用,使 PCI 成为选定患者(尤其是合并症患者和有 CABG 禁忌症的患者)的可行替代方案。本综述分析了在 LMCAD 患者中比较 CABG 与 PCI 的最重要研究。
{"title":"Evidence-based Management of Left Main Coronary Artery Disease","authors":"G. Torres-Ruiz, Nuria Mallofré-Vila, P. Rojas-Flores, Pablo Carrión-Montaner, E. Bosch-Peligero, Daniel Valcárcel-Paz, Ada Cardiel-Perez, J. Guindo-Soldevila, Antonio Martínez-Rubio","doi":"10.15420/ecr.2023.36","DOIUrl":"https://doi.org/10.15420/ecr.2023.36","url":null,"abstract":"Left main coronary artery disease (LMCAD) is associated with high morbidity and mortality due to the large myocardial mass at risk. Although medical treatment may be an option in selected low-risk patients, revascularisation is recommended to improve survival in the majority of patients presenting with a significant left main stenosis. In the past decade, multiple randomised clinical trials and meta-analyses have compared coronary artery bypass grafting surgery (CABG) versus percutaneous coronary intervention (PCI), finding controversial results. The strategy for LMCAD revascularisation is still challenging. Coronary anatomy complexity, clinical features and patient preferences are key elements to be considered by the heart team. The current guidelines define CABG as standard therapy, but the continuous improvements in PCI techniques, the use of intracoronary imaging and functional assessment make PCI a feasible alternative in selected patients, particularly in those with comorbidities and contraindications to CABG. This review analyses the most important studies comparing CABG versus PCI in patients with LMCAD.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":" 4","pages":""},"PeriodicalIF":3.0,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138961117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 2 根据患者情况选择非维生素 K 拮抗剂口服抗凝药预防心房颤动患者中风:越南专家的观点。第二部分
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-12-15 DOI: 10.15420/ecr.2023.25
Minh That Ton, T. H. Q. Ho, Viet Lan Nguyen, Hung Manh Pham, S. Hoang, Nhan Thanh Vo, Thai Quoc Nguyen, Linh Tran Pham, Ton Duy Mai, Thang Huy Nguyen
Part 1 of this review provided an overview of AF in Vietnam, with a particular focus on primary and secondary stroke prevention. Part 2 explores the management of AF in special, high-risk and clinically common patient populations including those with renal impairment, diabetes, the elderly, and those with coronary artery disease. Furthermore, Part 2 addresses the challenges posed by patients with AF who have a bioprosthetic valve, a group situated in a grey area of consideration. Managing AF in these patient groups presents unique clinical challenges that require careful consideration. Physicians are tasked with addressing specific clinical questions to identify the optimal anticoagulation strategy for each individual. To inform these decisions, subgroup analyses from pivotal studies are presented alongside real-world data derived from clinical practice. By synthesising available information and considering the nuanced clinical context, the aim is to provide informed perspectives that align with current medical knowledge and contribute to the enhancement of patient care in these challenging scenarios.
本综述的第 1 部分概述了越南的房颤情况,尤其侧重于中风的一级和二级预防。第二部分探讨了心房颤动在特殊、高风险和临床常见患者群体中的管理,这些患者包括肾功能受损者、糖尿病患者、老年人和冠心病患者。此外,第二部分还探讨了患有生物人工瓣膜的房颤患者所面临的挑战,这一群体处于考虑的灰色地带。这些患者群体的房颤管理面临着独特的临床挑战,需要仔细考虑。医生的任务是解决特定的临床问题,为每个人确定最佳的抗凝策略。为了给这些决策提供依据,我们将对关键研究中的亚组分析与临床实践中获得的真实数据一并进行介绍。通过综合现有信息并考虑微妙的临床背景,旨在提供符合当前医学知识的明智观点,并有助于在这些具有挑战性的情况下加强对患者的护理。
{"title":"Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 2","authors":"Minh That Ton, T. H. Q. Ho, Viet Lan Nguyen, Hung Manh Pham, S. Hoang, Nhan Thanh Vo, Thai Quoc Nguyen, Linh Tran Pham, Ton Duy Mai, Thang Huy Nguyen","doi":"10.15420/ecr.2023.25","DOIUrl":"https://doi.org/10.15420/ecr.2023.25","url":null,"abstract":"Part 1 of this review provided an overview of AF in Vietnam, with a particular focus on primary and secondary stroke prevention. Part 2 explores the management of AF in special, high-risk and clinically common patient populations including those with renal impairment, diabetes, the elderly, and those with coronary artery disease. Furthermore, Part 2 addresses the challenges posed by patients with AF who have a bioprosthetic valve, a group situated in a grey area of consideration. Managing AF in these patient groups presents unique clinical challenges that require careful consideration. Physicians are tasked with addressing specific clinical questions to identify the optimal anticoagulation strategy for each individual. To inform these decisions, subgroup analyses from pivotal studies are presented alongside real-world data derived from clinical practice. By synthesising available information and considering the nuanced clinical context, the aim is to provide informed perspectives that align with current medical knowledge and contribute to the enhancement of patient care in these challenging scenarios.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"97 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138997611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 1 根据患者情况选择非维生素 K 拮抗剂口服抗凝药预防心房颤动患者中风:越南专家的观点。第一部分
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-12-15 DOI: 10.15420/ecr.2023.24
T. H. Q. Ho, Minh That Ton, Viet Lan Nguyen, Hung Manh Pham, S. Hoang, Nhan Thanh Vo, Thai Quoc Nguyen, Linh Tran Pham, Ton Duy Mai, Thang Huy Nguyen
In Asia, especially Vietnam, AF is a common arrhythmia and is linked to a higher risk of stroke and systemic embolism. Anticoagulation therapy for stroke prevention in AF patients can result in bleeding complications. To effectively manage AF, adopting appropriate anticoagulation and addressing modifiable risk factors are crucial. Vietnamese clinicians are particularly interested in non-vitamin K antagonist oral anticoagulants (NOACs), a recent development in AF treatment. However, the lack of head-to-head trials comparing NOACs makes selecting a specific NOAC challenging. This review aims to provide a comprehensive overview of the available clinical evidence on NOACs for stroke prevention in AF to assist clinicians in making informed decisions and improving treatment outcomes in patients with AF. The first part of this review will present the current landscape of AF in Vietnam, focusing on AF prevalence and highlighting gaps in clinical practice. Furthermore, this part extensively discusses the anticoagulation strategy for both primary and secondary stroke prevention in AF.
在亚洲,尤其是越南,房颤是一种常见的心律失常,与中风和全身性栓塞的高风险有关。心房颤动患者为预防中风而进行的抗凝治疗可能会导致出血并发症。要有效控制心房颤动,采取适当的抗凝治疗和应对可改变的风险因素至关重要。越南临床医生对非维生素 K 拮抗剂口服抗凝药(NOACs)尤其感兴趣,这是心房颤动治疗的最新进展。然而,由于缺乏对 NOACs 进行头对头比较的试验,因此选择特定的 NOACs 具有挑战性。本综述旨在全面概述 NOACs 用于房颤卒中预防的现有临床证据,以帮助临床医生做出明智的决定并改善房颤患者的治疗效果。综述的第一部分将介绍越南心房颤动的现状,重点关注心房颤动的患病率,并强调临床实践中存在的差距。此外,这一部分还将广泛讨论心房颤动中风一级和二级预防的抗凝策略。
{"title":"Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 1","authors":"T. H. Q. Ho, Minh That Ton, Viet Lan Nguyen, Hung Manh Pham, S. Hoang, Nhan Thanh Vo, Thai Quoc Nguyen, Linh Tran Pham, Ton Duy Mai, Thang Huy Nguyen","doi":"10.15420/ecr.2023.24","DOIUrl":"https://doi.org/10.15420/ecr.2023.24","url":null,"abstract":"In Asia, especially Vietnam, AF is a common arrhythmia and is linked to a higher risk of stroke and systemic embolism. Anticoagulation therapy for stroke prevention in AF patients can result in bleeding complications. To effectively manage AF, adopting appropriate anticoagulation and addressing modifiable risk factors are crucial. Vietnamese clinicians are particularly interested in non-vitamin K antagonist oral anticoagulants (NOACs), a recent development in AF treatment. However, the lack of head-to-head trials comparing NOACs makes selecting a specific NOAC challenging. This review aims to provide a comprehensive overview of the available clinical evidence on NOACs for stroke prevention in AF to assist clinicians in making informed decisions and improving treatment outcomes in patients with AF. The first part of this review will present the current landscape of AF in Vietnam, focusing on AF prevalence and highlighting gaps in clinical practice. Furthermore, this part extensively discusses the anticoagulation strategy for both primary and secondary stroke prevention in AF.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"26 64","pages":""},"PeriodicalIF":3.0,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139000601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Evolution of Coronary Artery Spasm: How the Pendulum Has Swung 冠状动脉痉挛的演变:钟摆是如何摆动的
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-09-01 DOI: 10.15420/ecr.2023.08
John F Beltrame, Peter Ong, Filippo Crea
{"title":"The Evolution of Coronary Artery Spasm: How the Pendulum Has Swung","authors":"John F Beltrame, Peter Ong, Filippo Crea","doi":"10.15420/ecr.2023.08","DOIUrl":"https://doi.org/10.15420/ecr.2023.08","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"53 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80392174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Gaps in Modern Heart Failure and Chronic Kidney Disease Research. 现代心力衰竭和慢性肾脏疾病研究的空白。
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-08-23 eCollection Date: 2023-01-01 DOI: 10.15420/ecr.2022.64
Simran Singh Parmar, Vasantha Muthuppalaniappan, Debasish Banerjee

Heart failure and chronic kidney disease are common conditions and often coexist. Modern clinical trials are not entirely representative of heart failure patients in the community with respect to age and sex. Despite this, another group of heart failure patients, those with advanced chronic kidney disease, are even less represented in modern clinical trials. This review summarises the evidence for heart failure therapies across age, sex and severity of chronic kidney disease, and outlines the need for further research in these populations.

心力衰竭和慢性肾脏疾病是常见的疾病,并且经常共存。现代临床试验并不能完全代表社区中心力衰竭患者的年龄和性别。尽管如此,另一组心力衰竭患者,即晚期慢性肾病患者,在现代临床试验中的代表性更低。这篇综述总结了不同年龄、性别和慢性肾脏疾病严重程度的心力衰竭治疗证据,并概述了在这些人群中进行进一步研究的必要性。
{"title":"Gaps in Modern Heart Failure and Chronic Kidney Disease Research.","authors":"Simran Singh Parmar,&nbsp;Vasantha Muthuppalaniappan,&nbsp;Debasish Banerjee","doi":"10.15420/ecr.2022.64","DOIUrl":"10.15420/ecr.2022.64","url":null,"abstract":"<p><p>Heart failure and chronic kidney disease are common conditions and often coexist. Modern clinical trials are not entirely representative of heart failure patients in the community with respect to age and sex. Despite this, another group of heart failure patients, those with advanced chronic kidney disease, are even less represented in modern clinical trials. This review summarises the evidence for heart failure therapies across age, sex and severity of chronic kidney disease, and outlines the need for further research in these populations.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e51"},"PeriodicalIF":3.0,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6e/ef/ecr-18-e51.PMC10481380.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10189106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on 'Leadless Pacemakers: Current Achievements and Future Perspectives'. 评论 "无铅起搏器:当前成就与未来展望 "发表评论。
IF 3.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-08-18 eCollection Date: 2023-01-01 DOI: 10.15420/ecr.2022.58
Zaki Akhtar, Manav Sohal, Mark M Gallagher
{"title":"Comment on 'Leadless Pacemakers: Current Achievements and Future Perspectives'.","authors":"Zaki Akhtar, Manav Sohal, Mark M Gallagher","doi":"10.15420/ecr.2022.58","DOIUrl":"10.15420/ecr.2022.58","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e50"},"PeriodicalIF":3.2,"publicationDate":"2023-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8b/84/ecr-18-e50.PMC10466268.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10138080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Utility of CT Coronary Angiography in Chronic Total Occlusion Percutaneous Coronary Intervention. CT冠状动脉造影在慢性完全闭塞经皮冠状动脉介入治疗中的应用。
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-08-18 eCollection Date: 2023-01-01 DOI: 10.15420/ecr.2022.61
Firas Yassin, Jawad Khan, Abdul Mozid, Derek Connolly, Vinoda Sharma

Chronic total occlusion (CTO) of the coronary arteries is a relatively common finding in routine coronary angiography. Of late, there has been considerable improvement in the success rate of percutaneous intervention for coronary CTO, attributed to technological advancement and skills development. CT coronary angiogram (CTCA) is a simple, non-invasive, and cost-effective test that aids in the diagnosis and management of coronary artery disease, including CTOs. The development of multi-slice CT and the use of 3D volume rendering images has revolutionised the diagnostic abilities of CTCA, with improvements in imaging quality and detailed anatomical and morphological characterisation of the plaque disease. In CTO percutaneous intervention, CTCA is used in pre-procedural planning, applying scoring systems to predict the likely success of the intervention as well as the post-procedural evaluation and follow-up. This review examines the different uses of CTCA in CTO intervention, its impact on successful recanalisation and the areas for future consideration.

冠状动脉慢性完全闭塞(CTO)是常规冠状动脉造影中相对常见的发现。最近,由于技术进步和技能发展,冠状动脉CTO经皮介入治疗的成功率有了显著提高。CT冠状动脉造影(CTCA)是一种简单、无创、成本效益高的检测方法,有助于诊断和治疗冠状动脉疾病,包括CTO。多层CT的发展和3D体积绘制图像的使用彻底改变了CTCA的诊断能力,提高了斑块疾病的成像质量和详细的解剖和形态学特征。在CTO经皮介入治疗中,CTCA用于术前计划,应用评分系统预测介入治疗的可能成功以及术后评估和随访。这篇综述考察了CTCA在CTO干预中的不同用途,它对成功的再通管的影响以及未来需要考虑的领域。
{"title":"The Utility of CT Coronary Angiography in Chronic Total Occlusion Percutaneous Coronary Intervention.","authors":"Firas Yassin,&nbsp;Jawad Khan,&nbsp;Abdul Mozid,&nbsp;Derek Connolly,&nbsp;Vinoda Sharma","doi":"10.15420/ecr.2022.61","DOIUrl":"10.15420/ecr.2022.61","url":null,"abstract":"<p><p>Chronic total occlusion (CTO) of the coronary arteries is a relatively common finding in routine coronary angiography. Of late, there has been considerable improvement in the success rate of percutaneous intervention for coronary CTO, attributed to technological advancement and skills development. CT coronary angiogram (CTCA) is a simple, non-invasive, and cost-effective test that aids in the diagnosis and management of coronary artery disease, including CTOs. The development of multi-slice CT and the use of 3D volume rendering images has revolutionised the diagnostic abilities of CTCA, with improvements in imaging quality and detailed anatomical and morphological characterisation of the plaque disease. In CTO percutaneous intervention, CTCA is used in pre-procedural planning, applying scoring systems to predict the likely success of the intervention as well as the post-procedural evaluation and follow-up. This review examines the different uses of CTCA in CTO intervention, its impact on successful recanalisation and the areas for future consideration.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e48"},"PeriodicalIF":3.0,"publicationDate":"2023-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bc/8d/ecr-18-e48.PMC10466269.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10138078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transvenous Lead Extraction: Work in Progress. 经静脉提取铅:正在进行中。
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-06-19 eCollection Date: 2023-01-01 DOI: 10.15420/ecr.2023.06
Zaki Akhtar, Manav Sohal, Mary N Sheppard, Mark M Gallagher

Cardiac implantable electronic devices are the cornerstone of cardiac rhythm management, with a significant number of implantations annually. A rising prevalence of cardiac implantable electronic devices coupled with widening indications for device removal has fuelled a demand for transvenous lead extraction (TLE). With advancement of tools and techniques, the safety and efficacy profile of TLE has significantly improved since its inception. Despite these advances, TLE continues to carry risk of significant complications, including a superior vena cava injury and mortality. However, innovative approaches to lead extraction, including the use of the jugular and femoral accesses, offers potential for further gains in safety and efficacy. In this review, the indications and risks of TLE are discussed while examining the evolution of this procedure from simple traction to advanced methodologies, which have contributed to a significant improvement in safety and efficacy.

心脏植入式电子设备是心律管理的基石,每年都有大量的植入式设备。心脏植入式电子设备的普及率不断上升,再加上设备移除适应症的扩大,刺激了对经静脉铅提取(TLE)的需求。随着工具和技术的进步,TLE的安全性和有效性自成立以来有了显著改善。尽管取得了这些进展,但TLE仍然存在重大并发症的风险,包括上腔静脉损伤和死亡。然而,创新的铅提取方法,包括使用颈静脉和股骨通道,为进一步提高安全性和疗效提供了潜力。在这篇综述中,讨论了TLE的适应症和风险,同时考察了该程序从简单牵引到先进方法的演变,这有助于显著提高安全性和有效性。
{"title":"Transvenous Lead Extraction: Work in Progress.","authors":"Zaki Akhtar,&nbsp;Manav Sohal,&nbsp;Mary N Sheppard,&nbsp;Mark M Gallagher","doi":"10.15420/ecr.2023.06","DOIUrl":"10.15420/ecr.2023.06","url":null,"abstract":"<p><p>Cardiac implantable electronic devices are the cornerstone of cardiac rhythm management, with a significant number of implantations annually. A rising prevalence of cardiac implantable electronic devices coupled with widening indications for device removal has fuelled a demand for transvenous lead extraction (TLE). With advancement of tools and techniques, the safety and efficacy profile of TLE has significantly improved since its inception. Despite these advances, TLE continues to carry risk of significant complications, including a superior vena cava injury and mortality. However, innovative approaches to lead extraction, including the use of the jugular and femoral accesses, offers potential for further gains in safety and efficacy. In this review, the indications and risks of TLE are discussed while examining the evolution of this procedure from simple traction to advanced methodologies, which have contributed to a significant improvement in safety and efficacy.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e44"},"PeriodicalIF":3.0,"publicationDate":"2023-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c7/44/ecr-18-e44.PMC10345938.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9880460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Pre-eclampsia and Cardiovascular Disease: From Pregnancy to Postpartum. 先兆子痫与心血管疾病:从妊娠到产后。
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-06-07 eCollection Date: 2023-01-01 DOI: 10.15420/ecr.2022.56
Veronica Giorgione, Matthew Cauldwell, Basky Thilaganathan

Hypertensive disorders of pregnancy (HDP) complicate approximately 10% of pregnancies. In addition to multiorgan manifestations related to endothelial dysfunction, HDP confers an increased risk of cardiovascular disease during delivery hospitalisation, such as heart failure, pulmonary oedema, acute MI and cerebrovascular events. However, the cardiovascular legacy of HDP extends beyond birth since these women are significantly more likely to develop cardiovascular risk factors in the immediate postnatal period and major cardiovascular disease in the long term. The main mediator of cardiovascular disease in women with a history of HDP is chronic hypertension, followed by obesity, hypercholesterolaemia and diabetes. Therefore, optimising blood pressure levels from the immediate postpartum period until the first months postnatally could have beneficial effects on the development of hypertension and improve long-term cardiovascular health. Peripartum screening based on maternal demographic, and clinical and echocardiographic data could help clinicians identify women with HDP at highest risk of developing postpartum hypertension who would benefit from targeted primary cardiovascular prevention.

妊娠期高血压疾病(HDP)使大约10%的妊娠复杂化。除了与内皮功能障碍相关的多器官表现外,HDP还会增加分娩住院期间患心血管疾病的风险,如心力衰竭、肺水肿、急性心肌梗死和脑血管事件。然而,HDP的心血管遗产延伸到出生后,因为这些女性在出生后不久更容易出现心血管风险因素,在长期内更容易患上主要心血管疾病。有HDP病史的女性心血管疾病的主要媒介是慢性高血压,其次是肥胖、高胆固醇血症和糖尿病。因此,从产后立即到产后第一个月,优化血压水平可以对高血压的发展产生有益影响,并改善长期心血管健康。基于产妇人口统计、临床和超声心动图数据的围产期筛查可以帮助临床医生确定HDP妇女患产后高血压的风险最高,这些妇女将受益于有针对性的初级心血管预防。
{"title":"Pre-eclampsia and Cardiovascular Disease: From Pregnancy to Postpartum.","authors":"Veronica Giorgione,&nbsp;Matthew Cauldwell,&nbsp;Basky Thilaganathan","doi":"10.15420/ecr.2022.56","DOIUrl":"10.15420/ecr.2022.56","url":null,"abstract":"<p><p>Hypertensive disorders of pregnancy (HDP) complicate approximately 10% of pregnancies. In addition to multiorgan manifestations related to endothelial dysfunction, HDP confers an increased risk of cardiovascular disease during delivery hospitalisation, such as heart failure, pulmonary oedema, acute MI and cerebrovascular events. However, the cardiovascular legacy of HDP extends beyond birth since these women are significantly more likely to develop cardiovascular risk factors in the immediate postnatal period and major cardiovascular disease in the long term. The main mediator of cardiovascular disease in women with a history of HDP is chronic hypertension, followed by obesity, hypercholesterolaemia and diabetes. Therefore, optimising blood pressure levels from the immediate postpartum period until the first months postnatally could have beneficial effects on the development of hypertension and improve long-term cardiovascular health. Peripartum screening based on maternal demographic, and clinical and echocardiographic data could help clinicians identify women with HDP at highest risk of developing postpartum hypertension who would benefit from targeted primary cardiovascular prevention.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e42"},"PeriodicalIF":3.0,"publicationDate":"2023-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b3/1c/ecr-18-e42.PMC10345941.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9880456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
European Cardiology Review
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1